Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Kitchen, Scott G ^a   Bennett, Michael ^a   Galić, Zoran ^a   Kim, Joanne ^a   Xu, Qing ^a   Young, Alan ^a   Lieberman, Alexis ^a   Joseph, Aviva ^b   Goldstein, Harris ^b   Ng, Hwee ^a   Yang, Otto ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; PEPTIDE ANTIBODY; SERYLLEUCYLTYROSYLASPARAGINYLTHREONYLVALYLALANYLTHREONYLLEUCINE; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR ANTIBODY; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; THYMOCYTE; ANIMAL; GENETIC ENGINEERING; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; MOUSE MUTANT; PHENOTYPE; SPECIES DIFFERENCE; VIROLOGY;

MUS;

ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CLONING, MOLECULAR; EPITOPES; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELLS; HIV; HUMANS; MICE; MICE, SCID; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; SPECIES SPECIFICITY; T-LYMPHOCYTES;

EID: 77949515006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008208     Document Type: Article

References (52)

1. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, et al. (2004) Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114: 450-462.
2. Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, et al. (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumorinfiltrating lymphocytes. J Immunol 177: 6548-6559.
3. Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, et al. (2005) Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 16: 457-472.
4. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, et al. (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163: 507-513.
5. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, et al. (2008) Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 82: 3078-3089.
6. Miles JJ, Silins SL, Burrows SR (2006) Engineered T cell receptors and their potential in molecular medicine. Curr Med Chem 13: 2725-2736.
7. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 74: 8207-8212.
8. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171: 3287-3295.
9. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
10. Rossi JJ, June CH, Kohn DB (2007) Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
11. Tian S, Maile R, Collins EJ, Frelinger JA (2007) CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol 179: 2952-2960.
12. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM (1989) Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342: 559-561.
13. Yang L, Baltimore D (2005) Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America 102: 4518-4523.
14. Yang L, Qin XF, Baltimore D, Van Parijs L (2002) Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proceedings of the National Academy of Sciences of the United States of America 99: 6204-6209.
15. van Lent AU, Nagasawa M, van Loenen MM, Schotte R, Schumacher TN, et al. (2007) Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol 179: 4959-4968.
16. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, et al. (2007) Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 67: 2425-2429.
17. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM (1990) Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med 172: 1055-1063.
18. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, et al. (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632-1639.
19. Akkina RK, Rosenblatt JD, Campbell AG, Chen IS, Zack JA (1994) Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 84: 1393-1398.
20. DiGiusto DL, Lee R, Moon J, Moss K, O'Toole T, et al. (1996) Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 87: 1261-1271.
21. Frohman MA (1994) On beyond classic RACE (rapid amplification of cDNA ends). PCR Methods Appl 4: S40-58.
22. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
23. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, et al. (2006) Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 119: 135-145.
24. Taguchi T, McGhee JR, Coffman RL, Beagley KW, Eldridge JH, et al. (1990) Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. Journal of Immunological Methods 128: 65-73.
25. Bristol GC, Gao LY, Zack JA (1997) Preparation and maintenance of SCID-hu mice for HIV research. Methods 12: 343-347.
26. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, et al. (1991) HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 147: 1512-1521.
27. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, et al. (1989) Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 86: 9514-9518.
28. Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, et al. (1996) Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. Journal of Virology 70: 5799-5806.
29. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411-1423.
30. Terstappen LW, Huang S, Picker LJ (1992) Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood 79: 666-677.
31. Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, et al. (2003) Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102: 1779-1787.
32. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, et al. (2007) Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 178: 4112-4119.
33. Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, et al. (1998) Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc Natl Acad Sci U S A 95: 3111-3116.
34. Kitchen SG, Korin Y, Roth MD, Landay A, Zack JA (1998) Costimulation of CD8+ lymphocytes induces CD4 expression and allows HIV-1 infection. J Virol 72: 9054-9060.
35. Kitchen SG, Whitmire JK, Jones NR, Galic Z, Kitchen CM, et al. (2005) The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A 102: 3794-3799.
36. Sullivan YB, Landay AL, Zack JA, Kitchen SG, Al-Harthi L (2001) Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology 103: 270-280.
37. Yang LP, Riley JL, Carroll RG, June CH, Hoxie J, et al. (1998) Productive infection of neonatal CD8+ lymphocytes by HIV-1. J Exp Med 187: 1139-1144.
38. Benito JM, Lopez M, Soriano V (2004) The role of CD8+ T-cell response in HIV infection. AIDS Rev 6: 79-88.
39. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
40. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3: 212-217.
41. Huynen MA, Neumann AU (1996) Rate of killing of HIV-infected T cells and disease progression. Science 272: 1962.
42. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE (2004) Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant 10: 143-155.
43. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, et al. (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
44. Brodie SJ, Patterson BK, Lewinsohn DA, Diem K, Spach D, et al. (2000) HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 105: 1407-1417.
45. Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, et al. (1997) Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 90: 2196-2206.
46. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, et al. (1999) In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 5: 34-41.
47. Galic Z, Kitchen SG, Subramanian A, Bristol G, Marsden MD, et al. (2009) Generation of T lineage cells from human embryonic stem cells in a feeder free system. Stem Cells 27: 100-107.
48. Amado RG, Jamieson BD, Cortado R, Cole SW, Zack JA (1999) Reconstitution of human thymic implants is limited by HIV breakthrough during antiretroviral therapy. J Virol 73: 6361-6369.
49. Kitchen SG, Killian S, Giorgi JV, Zack JA (2000) Functional reconstitution of thymopoiesis following HIV infection. J Virol 74: 2943-2948.
50. Withers-Ward ES, Amado RG, Koka PS, Jamieson BD, Kaplan AH, et al. (1997) Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med 3: 1102-1109.
51. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, et al. (2004) Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15: 251-262.
52. Mitsuyasu R, Merigan TC, Carr A, Zack JA, Winters MA, et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine 15: 285-292.